TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Influenza
Pre-pandemic flu vaccine candidate with adjuvant shows good immune response in trial
January 17th, 2006
Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced that preliminary results of clinical trials fielded in France of an adjuvanted candidate H5N1 pre-pandemic influenza vaccine demonstrated a good immune response in a significant number of volunteers. This is the first trial of an H5N1 pre-pandemic influenza vaccine candidate that compared vaccines with and without adjuvants. Preliminary results showed that the vaccine was safe and well-tolerated in 300 healthy volunteers. A 30 microgram-dose with an adjuvant in a two-dose regimen demonstrated an immune response at levels consistent with requirements of regulatory agencies...
Source: TB & Outbreaks Week (2006-01-17)
|
